Target family: Calcitonin receptors (type: gpcr)
Target: AMY<sub>2</sub> receptor

Ligand: adrenomedullin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 9.2 pEC50
Reference (Journal): Novel calcitonin-(8-32)-sensitive adrenomedullin receptors derived from co-expression of calcitonin receptor with receptor activity-modifying proteins.
Published in: Biochem Biophys Res Commun

Ligand: adrenomedullin 2/intermedin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 6 pEC50
Reference (Journal): The pharmacology of adrenomedullin 2/intermedin.
Published in: Br J Pharmacol

Ligand: α-CGRP (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pEC50
Reference (Journal): Novel calcitonin-(8-32)-sensitive adrenomedullin receptors derived from co-expression of calcitonin receptor with receptor activity-modifying proteins.
Published in: Biochem Biophys Res Commun

Ligand: α-CGRP (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pEC50
Reference (Journal): Characterization of the human calcitonin gene-related peptide receptor subtypes associated with receptor activity-modifying proteins.
Published in: Mol Pharmacol

Ligand: α-CGRP (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pEC50
Reference (Journal): Pharmacological discrimination of calcitonin receptor: receptor activity-modifying protein complexes.
Published in: Mol Pharmacol

Ligand: amylin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pEC50
Reference (Journal): Characterization of the human calcitonin gene-related peptide receptor subtypes associated with receptor activity-modifying proteins.
Published in: Mol Pharmacol

Ligand: amylin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pEC50
Reference (Journal): Pharmacological characterization of receptor-activity-modifying proteins (RAMPs) and the human calcitonin receptor.
Published in: J Pharmacol Toxicol Methods

Ligand: amylin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pEC50
Reference (Journal): Activity of pramlintide, rat and human amylin but not Aβ1-42 at human amylin receptors.
Published in: Endocrinology

Ligand: amylin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pEC50
Reference (Journal): Activity of pramlintide, rat and human amylin but not Aβ1-42 at human amylin receptors.
Published in: Endocrinology

Ligand: calcitonin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: yes
Approval source: FDA (1986)
Median affinity: 11.4 pEC50
Reference (Journal): Pharmacological characterization of receptor-activity-modifying proteins (RAMPs) and the human calcitonin receptor.
Published in: J Pharmacol Toxicol Methods

Ligand: pramlintide (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: yes
Approval source: FDA (2005)
Primary target: no
Median affinity:  pEC50
Reference (Journal): Activity of pramlintide, rat and human amylin but not Aβ1-42 at human amylin receptors.
Published in: Endocrinology

Ligand: [125I]BH-AMY (rat, mouse) (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pKd

Ligand: Tyr0α-CGRP (human) (Peptide)
Interaction type: Agonist
Action: Full agonist
Median affinity: 8.3 pEC50
Reference (Journal): Characterization of the human calcitonin gene-related peptide receptor subtypes associated with receptor activity-modifying proteins.
Published in: Mol Pharmacol